July 3, 2019 — Artificial intelligence (AI) breast cancer screening specialist Therapixel announced the appointment of Matthieu Leclerc-Chalvet as chief executive officer on June 14, 2019. This follows a 5 million euros series A fundraising, and the appointment of Sacha Loiseau as chairman of the board. Leclerc-Chalvet is also joining the board of directors.
Leclerc-Chalvet brings 30 years of experience in the development and commercialization of medical devices. After 20 years abroad, working for multinational organizations as well as start-ups, he chose to return to France to share his experience with Therapixel. Until now, Leclerc-Chalvet was managing director of Mirada Medical, a British company specialized in medical imaging software, where he orchestrated a pivot towards AI, leading to the launch of the first AI software in radiotherapy.
Leclerc-Chalvet declared, “I am thrilled to join a team of such technical and scientific excellence, and to bring my strategic and operational expertise in adoption of medical technology innovation globally.”
This appointment allows Therapixel co-founder and interim CEO Pierre Fillard to focus on his role of chief scientific officer (CSO). He will work alongside Leclerc-Chalvet on completing the AI breast cancer screening product and going through the regulatory approvals leading to the commercial launch.
Read the article "Therapixel Wins the Digital Mammography Challenge"
For more information: www.therapixel.com
April 20, 2026 
